A Novel Clinical Scoring Model for Interventional Therapy in Chronic Total Occlusion of the Coronary Artery

Table 7

Comparison of different CTO operators.

	I group; (<5, <60)	II group; (<5, ≥60)	III group; (≥5, <60)	IV group; (<90%)	V group; (≥90%)	F/χ^2
CTO-PCI number	N = 5	N = 6	N = 13	N = 75	N = 45
Age (years)	67.00 ± 6.78	60.83 ± 9.89	59.62 ± 14.22	62.23 ± 11.72	62.44 ± 10.79	0.41	0.80
Male	3 (60.0%)	3 (50.0%)	12 (92.3%)	57 (76.0%)	41 (91.1%)	5.22	0.07
BMI (kg/m^2)	24.78 ± 2.67	23.61 ± 2.92	24.43 ± 3.62	25.31 ± 2.21	25.09 ± 2.53	1.73	0.62
Hypertension	4 (80.0%)	3 (50.0%)	8 (61.5%)	57 (76.0%)	31 (68.9%)	1.85	0.40
Hyperlipidemia	3 (60.0%)	5 (83.3%)	11 (84.6%)	39 (52.0%)	23 (51.1%)	6.16	0.05
Impaired glucose tolerance	2 (40.0%)	0	3 (23.1%)	30 (40.0%)	17 (37.8%)	2.97	0.23
Smoking	0	0	13 (100.0%)	35 (46.7%)	22 (48.9%)	0.41	0.81
Previous PCI history	1 (20.0%)	5 (83.3%)	3 (23.1%)	31 (41.3%)	26 (57.8%)	3.87	0.14
Previous CABG history	0	0	0	1(1.3%)	0	1.31	0.52
Previous MI history	2 (40.0%)	1 (16.7%)	6 (46.2%)	23 (30.7%)	13 (28.9%)	0.57	0.75
≥NYHA III	2 (40.0%)	0	6 (46.2%)	26 (34.7%)	17 (37.8%)	0.17	0.92
≥CKD III	1 (20.0%)	1 (16.7%)	0	5 (6.7%)	7 (15.6%)	2.45	0.29
Acute coronary syndrome	5 (100.0%)	4 (66.7%)	13 (100.0%)	69 (92.0%)	39 (86.7%)	0.93	0.63
LVEF＜40%	0	1 (16.7%)	2 (15.4%)	6 (8.0%)	4 (8.9%)	0.42	0.81
Angiographic features
CTO target vessel						1.90	0.49
LAD	3 (60.0%)	3 (50.0%)	5 (38.5%)	29 (38.7%)	21 (46.7%)
LCX	0	0	2 (15.4%)	6 (8.0%)	6 (13.3%)
RCA	2 (40.0%)	3 (50.0%)	6 (46.2%)	39 (52.0%)	18 (40.0%)
LM	0	0	0	1 (1.3%)	0
Collateral circulation, Rentrop＜2	2 (40.0%)	1 (16.7%)	4 (30.8%)	23 (30.7%)	16 (13.3%)	0.41	0.86
Blunt occlusion	3 (60.0%)	3 (50.0%)	7 (53.8%)	36 (48.0%)	34 (75.6%)	8.89	0.01
Calcification	1 (20.0%)	0	4 (30.8%)	25 (33.3%)	27 (60.0%)	12.33	<0.01
Curvature	4 (80.0%)	5 (83.3%)	12 (92.3%)	68 (90.7%)	42 (93.3%)	0.82	0.63
Occlusion length ≥20 mm	3 (60.0%)	6 (100.0%)	12 (92.3%)	66 (90.7%)	40 (88.9%)	0.35	0.98
Distal occlusion	2 (40.0%)	2 (33.3%)	6 (46.2%)	38 (50.7%)	30 (66.7%)	4.71	0.10
Initial occlusion	3 (60.0%)	3 (50.0%)	6 (46.2%)	34 (45.3%)	23 (51.1%)	4.26	0.81
In-stent occlusion	1 (20.0%)	0	0	11 (14.7%)	8 (17.8%)	3.08	0.21
J-CTO score	2.20 ± 0.84	2.33 ± 1.03	3.08 ± 1.19	3.03 ± 0.92	3.42 ± 0.87	3.67	<0.01
PROGRESS score	1.20 ± 0.84	0.67 ± 0.82	1.23 ± 1.09	1.23 ± 0.97	1.60 ± 0.86	1.96	0.10
ORA score	1.40 ± 0.55	1.00 ± 1.55	1.23 ± 0.83	1.27 ± 1.12	1.42 ± 1.10	0.29	0.88
Recharge score	2.60 ± 1.14	2.67 ± 1.21	3.15 ± 0.99	3.12 ± 0.94	3.6 ± 1.03	2.80	<0.05
Operator score	3.80 ± 0.84	2.33 ± 1.86	2.77 ± 1.30	2.03 ± 1.16	0.73 ± 1.32	14.21	<0.01
PCI features
Forward single-guidewire technology	1 (20.0%)	5 (83.3%)	12 (92.3%)	53 (70.7%)	23 (51.1%)	5.95	0.05
Forward double-guidewire technology	1 (20.0%)	1 (16.7%)	1 (7.7%)	15 (20.0%)	20 (44.4%)	11.51	<0.01
Intravascular ultrasound guidance/exploration	1 (20.0%)	1 (16.7%)	2 (15.4%)	13 (17.3%)	19 (42.2%)	10.36	<0.01
Intervention strategy conversion	1 (20.0%)	0	4 (30.8%)	24 (32.0%)	19 (42.2%)	3.35	0.19
7F guide tube	3 (20.0%)	4 (66.7%)	10 (76.9%)	43 (57.3%)	29 (64.4%)	1.60	0.45
X-ray fluoroscopy time	78.50 ± 27.58	73.80 ± 26.73	78.46 ± 11.91	67.35 ± 17.66	63.37 ± 17.45	10.12	<0.05
Dosage of the contrast agent	215.00 ± 91.92	192.00 ± 55.41	197.69 ± 42.65	178.68 ± 44.25	172.21 ± 40.51	4.53	0.34
CTO-PCI technical success	40.0%	83.3%	100%	90.7%	95.6%	100.25	<0.01
CTO-PCI procedural success	40.0%	83.3%	100%	89.3%	91.1%	141.29	<0.01